Le Lézard
Classified in: Health
Subject: SVY

UK Coagulation Market Future Horizons and Growth Strategies 2021: Analyzers and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities


NEW YORK, Nov. 17, 2017 /PRNewswire/ --

Complete report $6,100.  DataPack (test volumes, sales forecasts, supplier shares) $3,950.

Read the full report: https://www.reportlinker.com/p05122000

Summary

This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market during the next five years. 

The report explores business and technological trends in the UK coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

Coagulation Tests

Activated Clotting Time (ACT) (1), Activated Protein C Resistance,
Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time,
D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII,  Factor IX,
Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII,
Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation,
Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen,
Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S,
Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time,
Von Willebrand's Factor Fav/Ag, and others.

Sales and Market Share Analysis

- Sales and market shares of major
instrument and reagent suppliers.

Competitive Assessments

- Extensive strategic profiles of
major suppliers and emerging market entrants.

Market Segmentation Analysis

- Comprehensive market
segmentation analysis, including:

   - Hospitals
   - Commercial/Private Laboratories

- Test volume forecasts for over 40 major procedures
by market segment.

Current and Emerging Products

- Review of established and emerging procedures.

- Comparison of automated and semi-automated
analyzers from Diagnostica Stago, Helena, IL,
Siemens, Sysmex and other suppliers.

Technology Review

- Analysis of current and emerging technologies
and their potential market applications.

- Comprehensive lists of companies developing
or marketing new technologies and products by test.

Strategic Recommendations

- Product development and business expansion
opportunities with significant market appeal.

- "Ideal" product models with tentative
prices and operating characteristics.

- Alternative market penetration
strategies for instrument and reagent suppliers.

- Potential market entry barriers and risks.
                                                                     
Contains 409 pages and 35 tables


Read the full report: https://www.reportlinker.com/p05122000

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...

at 17:49
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of...



News published on and distributed by: